Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Ascites × danvatirsen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1 Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2 Turcot syndrome 1 Squamous Cell Carcinoma of Head and Neck 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Lung Neoplasms 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Ascites 1

Interventions

sintilimab 1 danvatirsen 1 catumaxomab 1 Octreotide 1 Blood Specimen Collection 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02417753 2017-05-15

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated

1 enrolled 10 charts

GastrointestinalGynecologic

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡